Overview

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca